Featured Sessions Recommended For You
These featured sessions offer a snapshot of the insights you can expect at the 5th Precision Medicine in Inflammatory Bowel. Download the Full Event Guide to unlock the complete agenda, view session details, and explore our expert speaker faculty.
Day One
Interactive Combination Therapy Mini-Workshop
Conference Day 1
Join this interactive workshop to navigate the opportunities and challenges of combination therapies in IBD. Working alongside your peers, you’ll evaluate different pathway targeting approaches using what you have learnt at the conference so far, and examine potential synergistic effects, discussing how combining MOAs may influence efficacy, safety, and off-target outcomes. Through a hands-on mix and match exercise, participants will hypothesize how different therapies may interact.
- Assessing complementary MOAs across different therapeutic classes through collaborative discussion exercises
- Exploring potential efficacy gains, resistance reduction, and toxicity considerations when combining treatments
- Generating new ideas and partnership opportunities that may inform future combination therapy strategies
Speakers:
Day One
INTERCEPT: Identifying At-Risk Crohn’s Patients Before Clinical Onset Using Predictive Biomarkers to Transform Precision Medicine
Conference Day 1
- Exploring the foundations and objectives of the INTERCEPT program, to intervene before symptomatic disease develops through predictive biomarkers
- Discussing how insights and biomarker discoveries from the METHYLOMIC project can inform future precision medicine in IBD
- Evaluating the pathway from biomarker discovery and validation to clinical implementation, looking forwards to preventing disease progression, improving patient selection and enabling earlier intervention
Speakers:
Day One
Identifying IBD Patient Populations Responsive to Anti-TL1A Therapies
Conference Day 1
- Examining emerging biomarkers associated with TL1A pathway activation and therapeutic response
- Developing approaches to identify patients most likely to benefit from TL1A-targeted therapies
- Improving trial efficiency and treatment outcomes through precision patient selection
Speakers:
Explore the 2027 Full Event Guide
- DISCOVER how biopharma is moving beyond ‘trial and error’ treatment approaches
- SHAPE your patient stratification strategies with predictive biomarker advances
- BUILD your understanding of the multi-omic, spatial-omics and AI-driven technologies
- LEARN how IBD is taking notes from oncology endpoints, to transform trial design
- CONNECT with 60+ leader of the Precision Medicine community across IBD drug development
A Sample of Who You Could Network With
